St. Jude Medical, Inc., has initiated a clinical study of the Prodigy™ neurostimulator, the first spinal cord stimulation (SCS) system able to deliver a proprietary mode of stimulation therapy called burst stimulation. The so-called SUNBURST™ (Success Using Neuromodulation with BURST) study will evaluate whether burst stimulation can be more effective in managing chronic pain than traditional tonic stimulation.
Spinal cord stimulation is a proven therapy that has been used to manage chronic pain for more than 40 years. The procedure involves the implant of a small neurostimulation device that powers thin wires placed along the spinal cord. The device emits low levels of electrical energy to interrupt or mask the transmission of pain signals to the brain. Patients with a traditional SCS system feel the mild pulses of energy as a tingling sensation called paresthesia. Early research indicates that burst stimulation may be able to deliver SCS therapy with little-to-no paresthesia and may be more effective than tonic stimulation, especially in managing complex back pain.
The Prodigy neurostimulator is a new investigational device with an expected 10-year battery life that requires recharging approximately once a week. The neurostimulator is designed to deliver both tonic and burst stimulation which may be able to address pain not fully managed by tonic stimulation alone.
The SUNBURST study is a randomized, prospective, multicenter, clinical IDE study, designed to demonstrate the safety and efficacy of the Prodigy neurostimulation system using tonic and burst stimulation therapy to manage patients with chronic intractable pain. A maximum of 442 patients will be enrolled at up to 50 sites in the U.S. The device remains investigational only in the US at this time.
“Severe chronic pain has a debilitating effect on patients’ lives,” said Dr. Timothy Deer, an interventional pain physician, and president and chief executive officer of the Center for Pain Relief in Charleston, W. Va. “Burst stimulation may provide us with a comprehensive approach to managing patients whose pain is not adequately controlled with tonic spinal cord stimulation alone, or for those who lose therapeutic benefit over time. Importantly, we hope to demonstrate that burst stimulation produces paresthesia-free pain relief which may make it ideal for those who can’t tolerate traditional stimulation.”
“The Prodigy spinal cord stimulation system with burst stimulation technology represents an important advancement in neurostimulation therapy,” said Dr. Mark D. Carlson, chief medical officer and vice president of global clinical affairs for St. Jude Medical. “We are excited to be leading the effort through the SUNBURST study to bring this novel stimulation mode to market, offering physicians a new alternative to manage patients suffering from severe chronic pain.”
Source: St.Jude Medical, Inc. , Business Wire